Regen BioPharma, Inc.
Regen BioPharma, Inc.
Your view on RGBPP
Overview
What the company does, where it operates, and who runs it.
About Regen BioPharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Raymond Koos
- Headquarters
- 4700 Spring Street, La Mesa, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David Raymond Koos
- Headquarters
- 4700 Spring Street, La Mesa, CA, US
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease.
The company is in the early stages of development of its products, and therapies. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Regen BioPharma, Inc., and the rating behind it. RGBPP last traded at $0.0019; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Regen BioPharma, Inc.. Starting points for Regen BioPharma, Inc.: beta 2.80 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Regen BioPharma, Inc.. Regen BioPharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Regen BioPharma, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Regen BioPharma, Inc.. Regen BioPharma, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Regen BioPharma, Inc. valued side by side against its closest peers. Regen BioPharma, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Regen BioPharma, Inc., and how their positions are changing. At a $89,893 market value, institutional positions materially move Regen BioPharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Regen BioPharma, Inc. executives and directors. Shares of Regen BioPharma, Inc. have traded between $0.0013 and $0.10 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Regen BioPharma, Inc.. Regen BioPharma, Inc. is a $89,893 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Regen BioPharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Regen BioPharma, Inc.. Coverage tracks Regen BioPharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.